Carfilzomib: Structure and biochemical features. | Download Scientific Diagram
The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia | Oncology - Frontiers
Carfilzomib in multiple myeloma
Molecules | Free Full-Text | Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease | HTML
Proteasome Inhibitors as Sensitizing Agents for Cancer Chemotherapy - ScienceDirect
Bortezomib-Resistant Mutant Proteasomes: Structural and Biochemical Evaluation with Carfilzomib and ONX 0914 - ScienceDirect
Carfilzomib for relapsed and refractory multiple myeloma | CMAR
Kyprolis FOCUS Phase 3 Study for Multiple Myeloma | Cancer Biology
Carfilzomib: Proteasome Inhibitors for Treatment of Multiple Myeloma Patients | Huateng Pharma | Pharmaceutical chemical reagents, PEG derivatives
JAMA Internal Medicine on Twitter: "In this review, we learn that immunomodulatory drugs (thalidomide, lenalidomide) and proteasome inhibitors (bortezomib, carfilzomib, ixazomib) have improved the overall survival of patients with #multiplemyeloma (MM ...
IJMS | Free Full-Text | Cellular Responses to Proteasome Inhibition: Molecular Mechanisms and Beyond | HTML
Mechanism of action of ixazomib. Notes: Ixazomib (MLN9708) administered... | Download Scientific Diagram
Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin - ScienceDirect
Resistance Mechanisms to Novel Therapies in Myeloma | IntechOpen
Carfilzomib - Wikipedia
Frontiers | Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma | Oncology
Updates to the drug‐resistant mechanism of proteasome inhibitors in multiple myeloma - Bai - 2021 - Asia-Pacific Journal of Clinical Oncology - Wiley Online Library
Proteasome inhibitors - ScienceDirect
Late Breaking Abstract – ASH 2019: DARZALEX®, KYPROLIS® and Dexamethasone Combination Improves PFS in Relapsed or Refractory Multiple Myeloma – OncoPrescribe
Carfilzomib - JADPRO
Frontiers | Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor | Oncology
New investigational drugs with single-agent activity in multiple myeloma | Blood Cancer Journal
Novel Targeted Agents in the Treatment of Multiple Myeloma - Hematology/Oncology Clinics
Figure 1 from Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma. | Semantic Scholar
Cancers | Free Full-Text | Proteasome Inhibitors for the Treatment of Multiple Myeloma | HTML
Kyprolis FOCUS Phase 3 Study for Multiple Myeloma | Cancer Biology
